MDxHealth/Sumitomo Sign Molecular Diagnostic Partnership

MDxHealth has signed a partnership agreement with Summit Pharmaceuticals International, a subsidiary of Sumitomo Corporation, to gain access to the Japanese market with its pharmaco molecular diagnostic (PharmacoMDx) epigenetic technologies and products. Expanding upon MDxHealth's PharmacoMDx programme, the partnership aims to provide companion diagnostic solutions, or theranostics, to pharmaceutical companies in the Japanese market. No financial terms have been disclosed. MDxHealth's PharmacoMDx team leverages next-generation and deep sequencing technologies for the identification and validation of powerful epigenetic biomarkers for novel therapeutics.

MDxHealth/Sumitomo Sign Molecular Diagnostic Partnership

MDxHealth has signed a partnership agreement with Summit Pharmaceuticals International, a subsidiary of Sumitomo Corporation, to gain access to the Japanese market with its pharmaco molecular diagnostic (PharmacoMDx) epigenetic technologies and products. Expanding upon MDxHealth's PharmacoMDx programme, the partnership aims to provide companion diagnostic solutions, or theranostics, to pharmaceutical companies in the Japanese market. No financial terms have been disclosed. MDxHealth's PharmacoMDx team leverages next-generation and deep sequencing technologies for the identification and validation of powerful epigenetic biomarkers for novel therapeutics.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.